Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.34 is 46% above its 5-year average of -0.63, near the high end of its 5-year range (-1.12–-0.33).
51.08% above its 12-month average of -0.70.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.13.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.34
EARNINGS PER SHARE (EPS) AVG TTM
-0.70
EARNINGS PER SHARE (EPS) AVG 3Y
-0.76
EARNINGS PER SHARE (EPS) AVG 5Y
-0.63
EARNINGS PER SHARE (EPS) AVG 10Y
-0.46
EARNINGS PER SHARE (EPS) AVG 15Y
-0.44
EARNINGS PER SHARE (EPS) AVG 20Y
-0.52
CURRENT VS TTM AVG
+51.08%
CURRENT VS 3Y AVG
+54.97%
CURRENT VS 5Y AVG
+45.60%
CURRENT VS 10Y AVG
+26.23%
CURRENT VS 15Y AVG
+21.97%
CURRENT VS 20Y AVG
+34.46%
Codexis, Inc.
Market Cap
$151.10M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.70
3Y Avg
-0.76
5Y Avg
-0.63
Market Cap
$151.98M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.53
3Y Avg
-0.57
5Y Avg
-0.55
Market Cap
$152.17M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.32
3Y Avg
-0.33
5Y Avg
-0.37
Market Cap
$149.98M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$148.77M
Earnings Per Share (EPS)
-0.61
TTM Avg
-0.35
3Y Avg
-0.32
5Y Avg
-0.30
Market Cap
$147.97M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.38
3Y Avg
-0.76
5Y Avg
-1.59
Market Cap
$155.42M
Earnings Per Share (EPS)
-1.13
TTM Avg
-2.24
3Y Avg
-2.81
5Y Avg
-2.43
Market Cap
$155.86M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.05
3Y Avg
-0.06
5Y Avg
-0.06
Market Cap
$145.22M
Earnings Per Share (EPS)
-12.04
TTM Avg
-8.05
3Y Avg
-55.02
5Y Avg
-123.25
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Codexis, Inc. (CDXS) | $151.10M | -0.34 | -0.70 | -0.76 | -0.63 |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.98M | -0.26 | -0.53 | -0.57 | -0.55 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.17M | -0.26 | -0.32 | -0.33 | -0.37 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.98M | -1.64 | -1.85 | -1.46 | -1.46 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.77M | -0.61 | -0.35 | -0.32 | -0.30 |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -0.51 | -0.38 | -0.76 | -1.59 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.42M | -1.13 | -2.24 | -2.81 | -2.43 |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | -0.05 | -0.06 | -0.06 |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.22M | -12.04 | -8.05 | -55.02 | -123.25 |
| Immuneering Corporation (IMRX)vs › | $145.21M | -1.04 | -1.66 | -1.77 | -1.60 |
Trailing EPS (TTM)
$-0.34
Forward EPS (Est.)
$-0.38
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.50 |
| 2024-12-31 | -0.89 |
| 2023-12-31 | -1.12 |
| 2022-12-31 | -0.51 |
| 2021-12-31 | -0.33 |
| 2020-12-31 | -0.40 |
| 2019-12-31 | -0.21 |
| 2018-12-31 | -0.21 |
| 2017-12-31 | -0.50 |
| 2016-12-31 | -0.21 |
| 2015-12-31 | -0.19 |
| 2014-12-31 | -0.50 |
| 2013-12-31 | -1.08 |
| 2012-12-31 | -0.84 |
| 2011-12-31 | -0.46 |
| 2010-12-31 | -0.35 |
| 2009-12-31 | -7.74 |
| 2008-12-31 | -16.63 |
| 2007-12-31 | -14.36 |
| 2006-12-31 | -6.88 |
